[HTML][HTML] The problems and pitfalls in systemic lupus erythematosus drug discovery
I Rodríguez-Pintó, G Espinosa… - Expert Opinion on Drug …, 2016 - Taylor & Francis
I Rodríguez-Pintó, G Espinosa, R Cervera
Expert Opinion on Drug Discovery, 2016•Taylor & FrancisTreatment of systemic lupus erythematosus (SLE) was historically based on clinical
experience and the evidence from observational studies, suggesting the clinical efficacy of
immunosuppressors.[1] However, new drug development in the era of evidence-based
medicine requires successful evaluation through different research phases. International
regulations in order to have a drug approved require two phase III controlled trials,
preferably superiority trials, and with open-label extension.
experience and the evidence from observational studies, suggesting the clinical efficacy of
immunosuppressors.[1] However, new drug development in the era of evidence-based
medicine requires successful evaluation through different research phases. International
regulations in order to have a drug approved require two phase III controlled trials,
preferably superiority trials, and with open-label extension.
Treatment of systemic lupus erythematosus (SLE) was historically based on clinical experience and the evidence from observational studies, suggesting the clinical efficacy of immunosuppressors.[1] However, new drug development in the era of evidence-based medicine requires successful evaluation through different research phases. International regulations in order to have a drug approved require two phase III controlled trials, preferably superiority trials, and with open-label extension.
Taylor & Francis Online